Eosinophilic Esophagitis: Steering Toward Success

Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea  Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS  © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503560 - 2.0 - 12/2025